Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Meetings Sponsor Program

The European Hematology Association (EHA) is a membership organization serving clinicians and researchers with an active interest in hematology in Europe and beyond. We bring together relevant stakeholders to promote excellence in patient care through education, research, and advocacy.

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

Call for interest

As a member of an EHA committee or taskforce, you’ll be instrumental in taking our ambitions to the next level.

Read more

Would you sell Peripheral Blood derived Stem Cells?

There are many things that are different in the United States of America (USA) and Europe. Some of these differences are in favour of society in the USA and some in Europe.

Read more

EHA-SLCH Hematology Tutorial on Hematological Disorders

Date: March 18-19, 2022

Format: Hybrid

EHA and the Sri Lanka College of Haematologists (SLCH) are happy to have successfully organized the EHA-SLCH Hematology Tutorial on Hematological Disorders on March 18 and 19, 2022.

Read more

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more